Cyclo: Surges on EMA boost for genetic disorder drug development

Cyclo Therapeutics

09/03/2021 17:22

** Shares of drug developer Cyclo Therapeutics  CYTH.O  jump
15.8% to $9.15
    ** CYTH says it has received positive opinion from a
European Medicines Agency (EMA) committee on its agreement with
the development plan for its lead drug candidate Trappsol Cyclo
to treat Niemann-Pick Disease Type C  urn:newsml:reuters.com:*:nBw37CTNqa
    ** With successful completion of the agreed development
plan, CYTH would be eligible for up to an additional two years
of marketing exclusivity in the EU, says co
    ** Niemann-Pick disease type C is a rare progressive genetic
disorder characterized by an inability of the body to transport
cholesterol and other fatty substances inside of cells
    ** CYTH had gained 81.6% YTD as of its last close

 (Reporting by Amruta Khandekar)
 ((Amruta.Khandekar@thomsonreuters.com;))